Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55)

被引:126
|
作者
Stoiber, H
Pinter, C
Siccardi, AG
Clivio, A
Dierich, MP
机构
[1] INST HYG,A-6020 INNSBRUCK,AUSTRIA
[2] LUDWIG BOLTZMANN INST AIDS FORSCH,A-6020 INNSBRUCK,AUSTRIA
[3] UNIV MILAN,DIPARTIMENTO BIOL & GENET SCI MED,LAB INTERDISCIPLINARE TECHNOL AVANZATE VIALBA,I-20157 MILAN,ITALY
[4] DIPARTIMENTO BIOL & TECHNOL SAN RAFFAELE,I-20132 MILAN,ITALY
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 1996年 / 183卷 / 01期
关键词
D O I
10.1084/jem.183.1.307
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Activation of the human complement system leads to complement deposition on human immunodeficiency virus (HIV) and HIV-infected cells without causing efficient complement-mediated lysis. Even in the presence of HIV-specific antibodies, only a few particles are destroyed, demonstrating that HIV is intrinsically resistant to human complement. Here we report that, in addition to decay accelerating factor (DAF) being partially responsible, human complement factor H (CFH), a humoral negative regulator of complement activation, is most critical for this resistance. In the presence of HIV-specific antibodies, sera devoid of CFH (total genetic deficiency or normal human serum depleted of CFH by affinity chromatography) lysed free virus and HIV-infected but not uninfected cells. In the presence of CFH, lysis of HIV was only obtained when binding of CFH to gp41 was inhibited by a monoclonal antibody against a main CFH-binding site in gp41. Since CFH is an abundant protein in serum, and high local concentration of CFH can be obtained at the surface of HIV as the result of specific interactions of CFH with the HIV envelope, it is proposed that the resistance of HIV and HIV-infected cells against complement-mediated lysis in vivo is dependent on DAF and CFH and can be overcome by suppressing this protection. Neutralization of HIV may be achieved by antibodies against DAF and, more importantly, antibodies against CFH-binding sites on HIV envelope proteins.
引用
收藏
页码:307 / 310
页数:4
相关论文
共 50 条
  • [31] THE ανβ3 INTEGRIN ASSOCIATES WITH COMPLEMENT REGULATORY PROTEIN DECAY ACCELERATING FACTOR (DAF/CD55) AND OSTEOPONTIN (OPN) IN ENDOMETRIAL CELLS DURING THE WINDOW OF IMPLANTATION.
    Palomino, W. A.
    Young, S. L.
    Barros, D.
    Kohen, P.
    Devoto, L.
    Lessey, B. A.
    FERTILITY AND STERILITY, 2010, 94 (04) : S216 - S217
  • [32] Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes
    Hidenori Taniguchi
    Christopher E Lowe
    Jason D Cooper
    Deborah J Smyth
    Rebecca Bailey
    Sarah Nutland
    Barry C Healy
    Alex C Lam
    Oliver Burren
    Neil M Walker
    Luc J Smink
    Linda S Wicker
    John A Todd
    BMC Genetics, 7
  • [33] Discovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetes
    Taniguchi, Hidenori
    Lowe, Christopher E.
    Cooper, Jason D.
    Smyth, Deborah J.
    Bailey, Rebecca
    Nutland, Sarah
    Healy, Barry C.
    Lam, Alex C.
    Burren, Oliver
    Walker, Neil M.
    Smink, Luc J.
    Wicker, Linda S.
    Todd, John A.
    BMC GENETICS, 2006, 7 (1)
  • [34] Improving decay-accelerating factor (DAF, CD55) by substituting a GPI-anchor with a membrane-targeting address
    White, J
    Giddings, N
    Esser, D
    Thurston, K
    Steward, M
    Bright, JR
    Morgan, BP
    Smith, GP
    Smith, RAG
    MOLECULAR IMMUNOLOGY, 2001, 38 (2-3) : 128 - 128
  • [35] Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55)
    Kuraya, M
    Fujita, T
    INTERNATIONAL IMMUNOLOGY, 1998, 10 (04) : 473 - 480
  • [36] Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia
    Lawrence, DW
    Bruyninckx, WJ
    Louis, NA
    Lublin, DM
    Stahl, GL
    Parkos, CA
    Colgan, SP
    JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (07): : 999 - 1010
  • [37] Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas
    Maenpaa, A
    Junnikkala, S
    Hakulinen, J
    Timonen, T
    Meri, S
    AMERICAN JOURNAL OF PATHOLOGY, 1996, 148 (04): : 1139 - 1152
  • [38] Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease
    Simpson, KL
    Jones, A
    Norman, S
    Holmes, CH
    AMERICAN JOURNAL OF PATHOLOGY, 1997, 151 (05): : 1455 - 1467
  • [39] Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55)
    Qian, YM
    Haino, M
    Kelly, K
    Song, WC
    IMMUNOLOGY, 1999, 98 (02) : 303 - 311
  • [40] Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer
    Holla, VR
    Wang, DZ
    Brown, JR
    Mann, JR
    Katkuri, S
    Dubois, RN
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (01) : 476 - 483